Aerpio Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

Aerpio Pharmaceuticals, Inc. ARPO, a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 8:00 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.

The presentation will be webcast live and may be accessed by visiting Aerpio's website at http://ir.aerpio.com/.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class compounds that activate Tie2 to treat ocular diseases and complications of diabetes. Tie2 is an important regulator of vascular stability and its down-regulation is found in patients with diabetes. Down-regulation is caused by activation of two inhibitors of Tie2, VE-PTP and Ang-2 due to hypoxia or tissue ischemia. The Company's lead compound, AKB-9778, is a systemically-administered small molecule activator of the Tie2 pathway (via highly selective and potent deactivation of VE-PTP) and is in clinical development for the treatment of non-proliferative diabetic retinopathy. AKB-9778 is also being investigated for its potential utility in treating diabetic nephropathy and an eyedrop formulation is in development as a potential treatment for open-angle glaucoma. For more information, please visit www.aerpio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005011/en/